Interview by Nicola Miller, RARE Revolution insider,
featuring Sebastien Coppe, chief executive officer and Pascal Piedbois chief medical officer,One2Treat

“We believe that what One2Treat offers is really answering both pharma perspectives and patients perspectives when it comes to rare disease, which is not that obvious for other therapeutic areas.” Sebastien

---